5-Amino-1MQ
5-amino-1-methylquinolinium
Single peptideSource verified
- Evidence
- Animal research
- Route
- Subcutaneous (animal research), Oral (community-reported)
- Schedule
- Once to three times daily in animal studies
- Vials
- 10 mg
View protocol7 citations
Research area
Metabolism & Weight protocols
Appetite, glucose, metabolic, and energy-balance pathways under study.
Educational reference only. Peptides Made Clear does not provide medical advice, dosing recommendations or administration guidance. Values shown are what published sources or reviewed records report, never a suggestion for personal use.
AICAR
Acadesine (5-aminoimidazole-4-carboxamide ribonucleotide)
Single peptideSource verified
- Evidence
- Animal research
- Route
- Human trials used intravenous infusion in hospital settings. Research vials are sold online; no approved or studied human vial route exists.
- Schedule
- Not established for any non-hospital use. No human study of vial-format use exists.
- Vials
- 50 mg
View protocol4 citations
Single peptideSource verified
- Evidence
- Animal research
- Route
- Studied orally in the obesity programme. Injectable forms sold online are unapproved and were not the subject of the pivotal trials.
- Schedule
- Trials used daily oral administration over 12 to 24 weeks.
- Vials
- No verified presentation recorded
View protocol1 citation
Single peptideSource verified
- Evidence
- Controlled human trials
- Route
- Subcutaneous injection, in every published human trial
- Schedule
- Once weekly in the published trial programme
- Vials
- 5 mg, 10 mg
View protocol6 citations
CJC-1295 with DAC
CJC-1295 with DAC (drug affinity complex), also known as CJC-1295-DAC and in development as ConjuChem CJC-1295
Single peptideSource verified
- Evidence
- Human observational or case reports
- Route
- Subcutaneous injection in the published human trials
- Schedule
- Published trial work used single or infrequent subcutaneous administration, consistent with a multi-day half-life. No approved regimen exists.
- Vials
- 2 mg, 5 mg
View protocol6 citations
CJC-1295 without DAC
CJC-1295 without DAC, commonly called modified GRF(1-29) or tetrasubstituted GHRH(1-29)
Single peptideSource verified
- Evidence
- Laboratory research
- Route
- Subcutaneous injection is the route described in non-clinical use. No approved or trial-established route exists for this molecule.
- Schedule
- Not established. No approved label or dedicated human trial defines a frequency.
- Vials
- 2 mg, 5 mg
View protocol6 citations
BlendSource verified
- Evidence
- Laboratory research
- Route
- Vendor listings describe subcutaneous injection of a reconstituted blend. No approved route exists for the combination.
- Schedule
- Not established for the combination. Any schedule shown by a seller is a marketing convention, not a studied regimen.
- Vials
- No verified presentation recorded
View protocol1 citation
Ipamorelin
Ipamorelin (NNC 26-0161), Aib-His-D-2-Nal-D-Phe-Lys-NH2
Single peptideSource verified
- Evidence
- Human observational or case reports
- Route
- Human trials used intravenous administration. Subcutaneous use is the common non-clinical route and is not supported by an approval or a route-matched efficacy trial we could verify.
- Schedule
- Not established. No approved regimen exists. Published clinical work used short investigational intravenous dosing in a hospital setting.
- Vials
- 2 mg, 5 mg, 10 mg
View protocol6 citations
Single peptideSource verified
- Evidence
- Early human research
- Route
- Oral supplementation, or intravenous levocarnitine in approved deficiency indications. Compounded intramuscular injections sold for fat loss are not approved.
- Schedule
- Approved deficiency treatment schedules are defined in labelling and set by a clinician.
- Vials
- No verified presentation recorded
View protocol1 citation
Single peptideSource verified
- Evidence
- Animal research
- Route
- Animal studies used injection. No approved human route.
- Schedule
- Not established in humans.
- Vials
- No verified presentation recorded
View protocol1 citation
Single peptideSource verified
- Evidence
- Controlled human trials
- Route
- Subcutaneous injection, in every published human trial
- Schedule
- Once weekly in the published phase 2 and phase 3 programmes
- Vials
- 5 mg, 10 mg, 15 mg, 20 mg, 30 mg
View protocol6 citations
Single peptideSource verified
- Evidence
- Controlled human trials
- Route
- Subcutaneous injection once weekly (Ozempic, Wegovy) and oral tablet once daily (Rybelsus)
- Schedule
- Once weekly subcutaneously in the approved injectable presentations; once daily orally in the approved tablet presentation
- Vials
- 2 mg, 5 mg, 10 mg, 15 mg
View protocol6 citations
Sermorelin
Sermorelin acetate, GHRH(1-29) amide
Single peptideSource verified
- Evidence
- Controlled human trials
- Route
- Subcutaneous injection, the route in the former approved labelling
- Schedule
- Former approved labelling described once-daily subcutaneous injection at bedtime in paediatric growth hormone deficiency.
- Vials
- 2 mg, 5 mg, 6 mg
View protocol6 citations
Tesamorelin
Tesamorelin (EGRIFTA, EGRIFTA WR), a stabilised 44-amino-acid GHRH analogue
Single peptideSource verified
- Evidence
- Controlled human trials
- Route
- Subcutaneous injection into the abdomen, per the approved label
- Schedule
- Once daily subcutaneous injection, continuously, per the approved label.
- Vials
- 1 mg, 5 mg, 10 mg
View protocol6 citations
Single peptideSource verified
- Evidence
- Controlled human trials
- Route
- Subcutaneous injection once weekly
- Schedule
- Once weekly subcutaneous administration in every approved presentation and published trial
- Vials
- 5 mg, 10 mg, 15 mg, 20 mg, 30 mg, 60 mg
View protocol6 citations